Multimodal glioma immunotherapy combining TLR9-targeted STAT3 antisense oligodeoxynucleotides with PD1 immune checkpoint blockade
Neuro-Oncology · 14.10.2025 · 27 (9) · 2296-2312
DOI: 10.1093/neuonc/noaf099 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 11.04.2025. Verfasst von Chia-Yang Hung und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immuno-Oncology, Beckman Research Institute, City of Hope National Medical Center, Duarte, California, USA. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Toll-Like Receptor 9, Immunotherapy, Glioma. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIH HHS, NCI NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
Background
Therapeutic resistance in glioblastoma (GBM) is multifactorial and results from genetic heterogeneity, the immunoprivileged localization, and the potently tolerogenic microenvironment. Signal transducer and activator of transcription 3 (STAT3) plays a key role in both glioma cell survival and immune evasion, reinforcing GBM resistance.
Methods
Here, we describe a new cell-selective and double-stranded STAT3 antisense oligonucleotide (CpG-STAT3dsASO) for targeting human/mouse glioma cells and GAMs but not T cells. The oligonucleotide safety and efficacy against orthotopic GBM was assessed in immunocompetent or immunodeficient mice.
Results
CpG-STAT3dsASO injected intracranially/intratumorally was well-tolerated and reduced progression of human U251 GBM xenotransplants and mouse GL261 or neural cell-derived QPP8 gliomas. Unlike the single-stranded oligonucleotide, local CpG-STAT3dsASO administration did not trigger type-I IFN-dependent neurotoxicities in immunocompetent mice within the therapeutic dose range. CpG-STAT3dsASO activated intratumoral GAMs, such as dendritic cells, macrophages and microglia, thereby expanding CD4+ Th1 cells while reducing TREG numbers. CpG-STAT3dsASO monotherapy did not have curative effects as it led to recruitment of only limited numbers of mostly exhausted effector CD8+ T cells. However, when combined with systemic PD1 inhibition, CpG-STAT3dsASO/anti-PD1 treatments caused regression of GL261 as well as immunotherapy-resistant QPP8 gliomas and resulted in long-term survival of the majority of mice. The combination treatment boosted CD8+ effector T-cell activity, while promoting their intratumoral interaction with activated CD4+ Th1 cells and activated macrophages as indicated by spatial transcriptomics.
Conclusions
Our results suggest rationale for GBM immunotherapy using CpG-STAT3dsASO to disrupt GAMs-dependent immune evasion, thereby restoring sensitivity to PD1 blockade and facilitating T-cell-mediated antitumor immune responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immuno-Oncology, Beckman Research Institute, City of Hope National Medical Center, Duarte, California, USA.
- Laboratory of Molecular Neurobiology, Nencki Institute of Experimental Biology, Polish Academy of Sciences, Warsaw, Poland.
- Department of Hematology & Hematopoietic Cell Transplantation, Beckman Research Institute, City of Hope National Medical Center, Duarte, California, USA.
- Division of Neurosurgery, Beckman Research Institute, City of Hope National Medical Center, Duarte, California, USA.
- DNA/RNA Synthesis Core Facility, Beckman Research Institute, City of Hope National Medical Center, Duarte, California, USA.
- Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
ORCID-Profile: Amy B Heimberger, Marcin Kortylewski
Förderung
- NIH HHS
- NCI NIH HHS
- NINDS NIH HHS
- NCI
- NIH
Zitieren
APA
Hung, C. Y., Kang, E. Y., Jacek, K., Yu, C., Zhang, X., Zhu, Y., Aftabizadeh, M., Wong, R. A., Badie, B., Świderski, P., Kamińska, B., Alizadeh, D., Heimberger, A. B., Brown, C. E., & Kortylewski, M. (2025). Multimodal glioma immunotherapy combining TLR9-targeted STAT3 antisense oligodeoxynucleotides with PD1 immune checkpoint blockade. Neuro-Oncology, 27(9), 2296-2312. https://doi.org/10.1093/neuonc/noaf099
Vancouver
Hung CY, Kang EY, Jacek K, Yu C, Zhang X, Zhu Y, et al. Multimodal glioma immunotherapy combining TLR9-targeted STAT3 antisense oligodeoxynucleotides with PD1 immune checkpoint blockade. Neuro-Oncology. 2025;27(9):2296-2312. doi:10.1093/neuonc/noaf099
BibTeX
@article{Hung2025,
author = {Hung, Chia-Yang and Kang, Elaine Y and Jacek, Karol and Yu, Chunsong and Zhang, Xiaowei and Zhu, Yicheng and Aftabizadeh, Maryam and Wong, Robyn A and Badie, Benham and Świderski, Piotr and Kamińska, Bożena and Alizadeh, Darya and Heimberger, Amy B and Brown, Christine E and Kortylewski, Marcin},
title = {Multimodal glioma immunotherapy combining TLR9-targeted STAT3 antisense oligodeoxynucleotides with PD1 immune checkpoint blockade},
journal = {Neuro-Oncology},
year = {2025},
volume = {27},
number = {9},
pages = {2296--2312},
doi = {10.1093/neuonc/noaf099}
}
EUVIMED